May. 1 at 8:51 PM
Bio-Rad Laboratories cut its 2026 revenue outlook and reported Q1 results that missed expectations, reflecting continued pressure on its core life sciences business. The company now sees full-year revenue ranging from a ~3% decline to 0.5% growth, versus its prior forecast of 0.5%–1.5% growth.
Q1 net loss totaled
$527.1 million, compared with net income of
$64 million a year earlier, primarily driven by a fair-value adjustment related to its investment in Sartorius AG. Adjusted EPS came in at
$1.89, below the
$1.98 consensus estimate.
The outlook revision and earnings miss add to investor concerns about near-term growth visibility. Shares have fallen 16.7% year-to-date, including Thursday’s drop.
$BIO